Years
|
Author
|
No.
|
Age (years)
|
Sex
|
Disease
|
Reconstruction
|
Biliary complication
|
Intervention
|
Distance (mm)
|
Duration from LDLT (months)
|
Period until removal of magnet (days)
|
Duration of internal catheter (weeks)
|
Outcome
|
---|
2005
|
Muraoka et al. [15]
|
1
|
1
|
F
|
FH
|
R-Y
|
Stricture
|
CJS
|
N/A
|
6
|
12
|
8
|
Success
|
| |
2
|
57
|
M
|
LC
|
R-Y
|
Stricture
|
CJS
|
N/A
|
7
|
12
|
8
|
Success
|
2005
|
Okajima et al. [16]
|
3
|
44
|
F
|
FH
|
D-D
|
Obstruction
|
CCS
|
N/A
|
12
|
42
|
12
|
Success
|
2008
|
Akita et al. [17]
|
4
|
34
|
F
|
N/A
|
D-D
|
Obstruction
|
CCS
|
5
|
0
|
21
|
0
|
Success
|
2008
|
Mita et al. [18]
|
5
|
0.5
|
F
|
FH
|
R-Y
|
Obstruction
|
CJS
|
N/A
|
1.5
|
12
|
N/A
|
Success
|
| |
6
|
59
|
F
|
LC
|
R-Y
|
Obstruction
|
CJS
|
N/A
|
5
|
25
|
N/A
|
Success
|
2009
|
Matsuno et al. [19]
|
7
|
53
|
M
|
N/A
|
D-D
|
Stricture
|
CCS
|
3
|
N/A
|
10
|
4.3
|
Success
|
2010
|
Marubashi et al. [13]
|
8
|
53
|
M
|
LC (HBV)
|
D-D
|
Dehiscence
|
CCS
|
N/A
|
6
|
63
|
72
|
Success
|
2010
|
Itoi et al. [20]
|
9
|
60
|
M
|
N/A
|
D-D
|
Obstruction
|
CCS
|
N/A
|
18
|
9
|
24
|
Success
|
2011
|
Kawakubo et al. [6]
|
10
|
56
|
M
|
LC (HCV)
|
R-Y
|
Obstruction
|
CJS
|
N/A
|
9
|
23
|
56
|
Success
|
2011
|
Jang et al. [14]
|
11
|
63
|
F
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
71
|
42
|
83
|
Success
|
| |
12
|
49
|
M
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
6
|
26
|
70
|
Success
|
| |
13
|
54
|
M
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
55
|
18
|
49
|
Success
|
| |
14
|
64
|
F
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
71
|
71
|
14
|
Success
|
| |
15
|
54
|
M
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
15
|
102
|
26.7
|
Success
|
| |
16
|
48
|
M
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
13
|
102
|
25.7
|
Success
|
| |
17
|
63
|
F
|
Liver failure (drug)
|
D-D
|
Stricture
|
CCS
|
30
|
107
|
–
|
–
|
Failure
|
| |
18
|
33
|
M
|
Liver failure (HAV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
5
|
33
|
26.7
|
Success
|
| |
19
|
61
|
M
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
4
|
14
|
25.4
|
Success
|
| |
20
|
54
|
M
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
9
|
181
|
7.3
|
Success
|
| |
21
|
52
|
M
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
1
|
153
|
N/A
|
Success
|
| |
22
|
51
|
M
|
LC (HBV)
|
D-D
|
Stricture
|
CCS
|
N/A
|
5
|
–
|
–
|
Failure
|
2014
|
Uemura et al. [21]
|
23
|
49
|
F
|
LC (HCV)
|
D-D
|
Obstruction
|
CCS
|
11
|
11
|
24
|
13
|
Success
|
2016
|
Ersoz et al. [22]
|
24
|
37
|
M
|
LC (HBV)
|
D-D
|
Dehiscence
|
CCS
|
15
|
12
|
13
|
N/A
|
Success
|
| |
25
|
54
|
F
|
LC (HBV, HDV)
|
D-D
|
Dehiscence
|
CCS
|
10
|
84
|
14
|
N/A
|
Success
|
| |
26
|
53
|
F
|
LC (HCV)
|
D-D
|
Dehiscence
|
CCS
|
10
|
14
|
42
|
N/A
|
Success
|
| |
27
|
63
|
M
|
LC (HBV)
|
D-D
|
Dehiscence
|
CCS
|
5
|
7
|
18
|
N/A
|
Success
|
| |
28
|
68
|
F
|
LC (HBV)
|
D-D
|
Dehiscence
|
CCS
|
10
|
6
|
22
|
N/A
|
Success
|
| |
29
|
54
|
M
|
LC (HBV)
|
D-D
|
Dehiscence
|
CCS
|
15
|
7
|
13
|
N/A
|
Success
|
2017
|
Saito et al. [23]
|
30
|
54
|
F
|
LC (PSC)
|
R-Y
|
Strangulated ileus
|
CDS
|
27
|
60
|
25
|
44
|
Success
|
2017
|
Parlak et al. [24]
|
31
|
68
|
F
|
LC (HCV)
|
D-D
|
Obstruction
|
CCS
|
2.5
|
14
|
7
|
36
|
Success
|
| |
32
|
52
|
M
|
LC (HBV)
|
D-D
|
Obstruction
|
CCS
|
3
|
22
|
10
|
N/A
|
Success
|
| |
33
|
55
|
M
|
LC (HBV)
|
D-D
|
Obstruction
|
CCS
|
4
|
16
|
2
|
36
|
Success
|
| |
34
|
58
|
M
|
LC (Cryptogenic)
|
D-D
|
Obstruction
|
CCS
|
6
|
34
|
14
|
48
|
Success
|
| |
35
|
38
|
F
|
LC (HBV)
|
D-D
|
Obstruction
|
CCS
|
3
|
38
|
12
|
48
|
Success
|
| |
36
|
63
|
F
|
LC (HCV)
|
D-D
|
Obstruction
|
CCS
|
3
|
13
|
2
|
44
|
Success
|
| |
37
|
52
|
M
|
LC (HBV)
|
D-D
|
Obstruction
|
CCS
|
4
|
60
|
10
|
N/A
|
Success
|
| |
38
|
54
|
M
|
LC (HBV)
|
D-D
|
Obstruction
|
CCS
|
5
|
15
|
–
|
–
|
Failure
|
| |
39
|
62
|
M
|
LC (Cryptogenic)
|
D-D
|
Obstruction
|
CCS
|
5
|
5
|
–
|
–
|
Failure
|
2018
|
Kubo
|
40
|
55
|
F
|
LC (PSC)
|
R-Y
|
Dehiscence
|
CJS
|
10
|
12
|
21
|
48
|
Success
|
| | | | | | |
Dehiscence
|
CJS
|
10
|
14
|
47
|
76
|
Success
|
|
Mean
| |
51.6
| |
s
| | | |
8.9
|
22.6
|
35.5
|
37.6
|
36/40(90.0%)
|
- FH fulminant hepatitis, LC liver cirrhosis, HAV hepatitis type A virus, HBV hepatitis type B virus, HCV hepatitis type C virus, PSC primary sclerosing cholangitis, D-D duct-to-duct anastomosis, R-Y Roux en Y anastomosis, CCS choledochocholedochostomy, CDS choledochoduodenostomy, CJS choledochojejunostomy, N/A not addressed